Nurix's Bexobrutideg Shows Durable Responses, 93% ORR in CLL/SLL; Reinforces Roche Partnership
NRIX sits 91% above its 52-week low of $8.195.
Summary
Nurix Therapeutics announced updated positive Phase 1a/b clinical data for its lead BTK degrader, bexobrutideg, in chronic lymphocytic leukemia (CLL/SLL). The data shows a 92.9% objective response rate in second-line patients and durable responses with a median progression-free survival of 22.1 months and an 83% ORR in heavily pretreated patients. This strong efficacy and consistent safety profile further validate the drug's potential and reinforce the value of the global collaboration with Roche announced three days ago. The company plans to advance a broad Phase 3 monotherapy program. The full data will be presented at the EHA Congress, which is ongoing.
At the time of this announcement, NRIX was trading at $15.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $8.20 to $22.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.